EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

A review on disease modifying pharmacologic therapies for sickle cell disease

Himil Mahadevia, Ben Ponvilawan, Ujjwal Madan, Parth Sharma, Hana Qasim, Anuj Shrestha

Annals of Hematology · 2025-02 · 104 (2) · 881-893

DOI: 10.1007/s00277-025-06216-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Hematology, online erschienen am 20.01.2025. Verfasst von Himil Mahadevia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Missouri-Kansas City, Kansas City, MO, 64108, USA. himil7777@gmail.com. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Antisickling Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sickle cell disease (SCD) is an inherited hematologic disease caused by sickle hemoglobin as the predominant RBC hemoglobin or by sickle hemoglobin in combination with other abnormal β-hemoglobin variants like HbC, HbD and others. Sickling of erythrocytes under deoxygenated conditions is the basis of inflammatory and thrombotic cascades which result in multiple serious complications, leading to early morbidity and mortality. While HLA-matched allogeneic bone marrow transplantation is potentially curative, it has considerable limitations due to potential severe toxicities. Despite slow progress towards novel therapeutic strategies for SCD and hydroxyurea being the sole medication that is shown to reduce vaso-occlusive events and mortality for almost 20 years, several pharmacological agents targeting different mechanisms have been examined in clinical trials and recently US- US-FDA-approved, including L-glutamine and crizanlizumab. Voxelotor was previously US-FDA-approved but has been voluntarily withdrawn from the market as the overall benefit did not outweigh the risks. Gene therapies based on CRISPR-Cas9 and lentiviral vectors have been very recently approved. However, excessive costs are a barrier to widespread use. Nonetheless, there is still a large area of unmet needs for patients with SCD, and further research towards better care is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellAntisickling AgentsHumansHydroxyureaAntibodies, Monoclonal, HumanizedGlutamineGenetic TherapyNitrilesPyrazolesBenzaldehydesPyrazines

Stichwörter der Autor:innen

CrizanlizumabHydroxyureaL-glutaminePharmacologic therapySickle cell diseaseVoxelotor

Substanzen

HydroxyureaAntisickling AgentsAntibodies, Monoclonal, HumanizedGlutaminecrizanlizumabvoxelotorNitrilesPyrazolesBenzaldehydesPyrazines

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Missouri-Kansas City, Kansas City, MO, 64108, USA. himil7777@gmail.com.
  • Department of Internal Medicine, University of Missouri-Kansas City, Kansas City, MO, 64108, USA.
  • Department of Internal Medicine, Section of Hematology/Oncology, University of Missouri-Kansas City, Kansas City, MO, 64108, USA.

Zitieren

APA

Mahadevia, H., Ponvilawan, B., Madan, U., Sharma, P., Qasim, H., & Shrestha, A. (2025). A review on disease modifying pharmacologic therapies for sickle cell disease. Annals of Hematology, 104(2), 881-893. https://doi.org/10.1007/s00277-025-06216-1

Vancouver

Mahadevia H, Ponvilawan B, Madan U, Sharma P, Qasim H, Shrestha A. A review on disease modifying pharmacologic therapies for sickle cell disease. Annals of Hematology. 2025;104(2):881-893. doi:10.1007/s00277-025-06216-1

BibTeX
@article{Mahadevia2025,
  author = {Mahadevia, Himil and Ponvilawan, Ben and Madan, Ujjwal and Sharma, Parth and Qasim, Hana and Shrestha, Anuj},
  title = {A review on disease modifying pharmacologic therapies for sickle cell disease},
  journal = {Annals of Hematology},
  year = {2025},
  volume = {104},
  number = {2},
  pages = {881--893},
  doi = {10.1007/s00277-025-06216-1}
}
Kostenlos starten →